Trials / Completed
CompletedNCT04676737
TTHX1114(NM141) in Combination With DWEK/DSO
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Trefoil Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label, single-treatment, with a concurrent non-treatment control
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTHX1114(NM141) | TTHX1114 |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2022-11-16
- Completion
- 2023-01-13
- First posted
- 2020-12-21
- Last updated
- 2023-11-07
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04676737. Inclusion in this directory is not an endorsement.